Quick Takeaways
- IDXG - INTERPACE BIOSCIENCES, INC. has 5 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 5 Insiders of INTERPACE BIOSCIENCES, INC.
- Symbol
- IDXG on OTC
- Location
- Parsippany, NJ
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 03 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
INTERPACE BIOSCIENCES, INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ampersand 2018 Limited Partnership | 10%+ Owner | $27,999,999 | Mixed | 20 Jan 2026 | ||
| 1315 Capital II, L.P. | 10%+ Owner | $19,000,000 | Mixed | 20 Jan 2026 | ||
| Christopher McCarthy | Chief Financial Officer | $94,518 | Mixed | 01 Feb 2024 | ||
| Thomas W. Burnell | President & CEO, Director | Mixed | 21 May 2021 | |||
| Vijay Aggarwal | Director | Mixed | 01 Feb 2022 |
Top shareholders of INTERPACE BIOSCIENCES, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Ampersand 2018 Limited Partnership |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
13,861,386
|
$27,999,999 | — | 20 Jan 2026 | |
| 1315 Capital II, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
9,405,941
|
$19,000,000 | — | 20 Jan 2026 | |
| Douglas M. Singer |
13D/G
|
— |
4.4%
|
195,742
|
$264,252 | -$42,260 | 10 Jan 2025 | |
| Christopher McCarthy |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
46,791
|
$94,518 | — | 01 Feb 2024 | |
| Thomas W. Burnell |
3/4/5
|
President & CEO, Director |
—
mixed-class rows
|
235,855
mixed-class rows
|
— | — | 21 May 2021 | |
| Vijay Aggarwal |
3/4/5
|
Director |
—
class O/S missing
|
28,000
|
— | — | 01 Feb 2022 |
Recent Insider Transactions by Companies or Individuals for INTERPACE BIOSCIENCES, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| 1315 Capital II, L.P. | IDXG | Common Stock | Conversion of derivative security | 9,405,941 | 9,405,941 | 20 Jan 2026 | Direct | |||
| 1315 Capital II, L.P. | IDXG | Series C Convertible Preferred Stock | Conversion of derivative security | -100% | -19,000 | 0 | 20 Jan 2026 | Direct | ||
| Ampersand 2018 Limited Partnership | IDXG | Common Stock | Conversion of derivative security | 13,861,386 | 13,861,386 | 20 Jan 2026 | Direct | |||
| Ampersand 2018 Limited Partnership | IDXG | Series C Convertible Preferred Stock | Conversion of derivative security | -100% | -28,000 | 0 | 20 Jan 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.